Parkinson's Disease Stem Cell Protocol
Targeted Evaluation Route for Spinal Degeneration & Disc Care
- Starting Price: $8,500 USD (Preliminary Planning Estimate)
- Location: Cali, Colombia
- Suggested Stay: 4 Days
- Administration: Systemic Intravenous (IV) & Intranasal Delivery
- Product & Dose: Umbilical Cord-Derived Mesenchymal Stem Cells (TRUSTEM BANK)
- Regulatory Status: Investigational Intervention
Important Medical Notice:
The cellular evaluation route for Parkinson’s disease is an investigational pathway focusing on systemic immunomodulation and neuroinflammatory responses. It must not be presented as a cure, guaranteed dopaminergic neuron regeneration, or an immediate substitute for prescribed levodopa, dopaminergic agonists, or indicated Deep Brain Stimulation (DBS).
Institutional Provider Details:
Legal Entity: STEM CELLS KYRON COLOMBIA SCKC
Facility Address: Calle 6 Oeste #24f-13, Cali, Colombia
Medical Director: Dr. Carlos Eduardo Rojas Martínez, MD (CEO)
Cell Processing Laboratory: TRUSTEM BANK
Clinical Patient Manager: Daniel Sanz
SCOPE OF SERVICE
(INCLUSIONS & EXCLUSIONS)
Included in the Package
- Pre-travel neurology records, MRI report, & medication review
- On-site medical consultation & physical examination in Cali
- Protocol-defined baseline imaging & safety lab review
- Cellular product explanation & laboratory quality reports
- Systemic IV and intranasal delivery & post-infusion monitoring
- Medical discharge summary for your home neurologist
- Structured remote follow-up at Weeks 4, 14, 36, and 52
Exclusions & Out-of-Pocket Expenses
- Flights, passports, visas, lodging, & daily meals
- Local transfers, travel insurance, & emergency evacuation
- Unscripted specialty consultations or extended hospital stays
- Ongoing physical, speech, occupational, or DBS therapy
- Emergency room care or unscripted complication treatments
- Repeat procedures or unquoted protocol adjustments
- Caregiver expenses or personal travel companions
CLINICAL ELIGIBILITY & REQUIRED DOCUMENTS
Potential Candidates for Evaluation:
Adults with confirmed Parkinson’s disease diagnosis seeking an investigational supportive route.
Documented motor symptom baseline (tremor, rigidity, bradykinesia, gait changes) and response history to dopaminergic therapy.
Ability to provide informed consent (or via authorized legal caregiver) and participate in follow-up.
Realistic expectations acknowledging that complete disease reversal or medication cessation cannot be guaranteed.
Situations Requiring Additional Evaluation or Exclusion:
Advanced cognitive decline or severe dementia impeding cooperation or informed consent.
Active systemic infection, severe dysphagia with high aspiration risk, or acute medical instability.
Active malignancy or history of unmonitored oncological disease.
Uncompensated cardiovascular, renal, or hepatic disease.
Severe unmanaged psychiatric disorders or acute psychosis.
- Detailed neurology history documenting disease duration, Hoehn & Yahr stage (if known), and main motor/non-motor symptoms.
- Complete list of current antiparkinsonian medications (levodopa/carbidopa, dopamine agonists, MAO-B inhibitors) with exact schedules.
- Recent Brain MRI reports and images (DICOM format preferred).
- Recent blood work (CBC, metabolic panel, liver/renal function) and cardiovascular assessment.
- Contact details for your home treating neurologist or primary care physician.
PROTOCOL SPECS & 4-DAY TIMELINE
Cellular Product Specifications:
Cell Type: Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs).
Manufacturing Laboratory: TRUSTEM BANK.
Dose & Route: Dosing based on body weight and clinical evaluation; administered via Systemic IV Infusion and targeted Intranasal delivery.
Quality Assurance: Certified post-thaw viability, sterility, endotoxin, and mycoplasma clearance reports.
4-Day Clinical Itinerary:
Pre-Travel (1 Week Prior): Neurology file review, clinical pre-selection, and budget confirmation.
Day 1 (Arrival in Cali): On-site neurological evaluation, physical assessment, and baseline safety labs.
Day 2 (Procedure Day): IV infusion and intranasal administration under continuous clinical monitoring.
Day 3 (Local Observation): Vital signs tracking, motor symptom check, and post-infusion observation.
Day 4 (Travel Clearance): Final clinical evaluation, medical discharge summary, and authorization for return flight.
Remote Follow-Up: Scheduled remote monitoring calls at Weeks 4, 14, 36, and 52.
POST-PROCEDURE RECOVERY & RISK DISCLOSURE
Post-Procedure Recovery Guidelines:
First 48 Hours: Rest, maintain adequate hydration, and log temperature or any unusual symptoms.
First Month: Continue taking all prescribed home antiparkinsonian medications exactly as directed by your home neurologist. Do not adjust dosages independently.
General Risks and Possible Complications:
Transient low-grade fever, mild fatigue, headache, or localized IV site irritation.
Temporary fluctuation in blood pressure or mild dizziness.
Rare allergic, infusional, or vascular reactions.
Absence of motor symptom improvement or financial loss.
FREQUENTLY ASKED QUESTIONS
1. Is cell therapy an approved cure for Parkinson's disease?
No. It is an investigational approach aimed at immunomodulation and neuroinflammation pathways, not a cure.
2. Will I be able to stop taking my Levodopa after the procedure?
No. You must continue all prescribed Parkinson’s medications. Any medication adjustment must be managed directly by your home neurologist over time.
3. Why is an intranasal route included alongside IV infusion?
Intranasal administration is used as a non-invasive supportive route aiming for direct mucosal-to-central nervous system delivery pathways.
4. What is included in the $8,500 USD starting price?
It covers pre-travel file evaluation, clinical consultations in Cali, baseline labs, cellular product, IV/intranasal administration, discharge report, and 12-month follow-up.
PRE-DECISION CHECKLIST
- I understand that stem cell therapy for Parkinson's disease is an investigational intervention.
- I know the cell source (UC-MSCs), administration routes (IV & Intranasal), and laboratory testing standards.
- I understand that I must continue taking my prescribed Parkinson's medications as directed.
- I have shared my complete neurological history, Brain MRI, and current medication list.
- I have consulted with my home neurologist or primary care physician prior to booking.
Connect with our clinical team to review motor symptoms, levodopa response, and candidate eligibility for our Parkinson's pathway.
+ (1) 305 400 1476
+ (57) 315 399 5608
